Small Bowel ObstructionSBONCT06101719
Use of a Water Soluble Contrast-Based Protocol to Assist in the Management of Pediatric Adhesive Small Bowel Obstruction
An observational study of Small Bowel Obstruction and Contrast Media Adverse Reaction, run by Children's Hospital Colorado at 9 sites in United States.
Trial summary
The goal of this prospective observational study is to evaluate the diagnostic and therapeutic utility of an enteral contrast challenge for pediatric patients with adhesive small bowel obstruction (ASBO). The aims are to 1. Determine if an enteral contrast challenge is safe in the evaluation of children with ASBO 2. Read more about this study
- Who is it for?
- Ages 1 year to 20 years
- Conditions the study is for
- Small Bowel Obstruction, Contrast Media Adverse Reaction
- What is being tested?
- Enteral contrast challenge
- How many people
- 136 participants
- Where
- 9 sitesUnited States
- Study dates
- 1 Oct 2020to 31 Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 20 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Children with adhesive small bowel obstruction admitted to one of 9 participating sites and underwent a trial of non operative management
Who may be able to join
- children 1-20 years
- diagnosed with an adhesive small bowel obstruction by an attending pediatric surgeon
- underwent a trial of nonoperative management on hospital admission
Who cannot join
- peritonitis
- suspicion of incarcerated or internal hernia
- active intra-abdominal malignancy
- inflammatory bowel disease
- less than four weeks since most recent abdominal operations
- pneumatosis
- pneumoperitoneum
- known contrast allergy
Trial locations and contacts
9 sites in 1 country.
9 sites in 1 country
United States9 sites
Children's Hospital Colorado
Aurora, Colorado, 80045
Children's Medical Center of Dallas
Dallas, Texas, 75390
Children's Hospital Los Angeles
Los Angeles, California, 90027
UCSF Benioff Children's Hospital
Oakland, California, 94609
Phoenix Children's Hospital
Phoenix, Arizona, 85006
Oregon Health Sciences University
Portland, Oregon, 97239
Primary Children's Hospital
Salt Lake City, Utah, 84113
Rady Children's Hospital
San Diego, California, 92123
Seattle Children's Hospital
Seattle, Washington, 98105
About this study
The goal of this prospective observational study is to evaluate the diagnostic and therapeutic utility of an enteral contrast challenge for pediatric patients with adhesive small bowel obstruction (ASBO). The aims are to
- Determine if an enteral contrast challenge is safe in the evaluation of children with ASBO
- Determine if an enteral contrast challenge decreases the need for operation among children with ASBO Children with ASBO who are cared for at one of 9 participating sites who undergo a trial of non operative management will be observed. Comparisons will be made between those who receive and enteral contrast challenge and those who do not. Outcomes to be evaluated include adverse events related to the contrast, rate of operative intervention, and hospital length of stay.
Read the detailed description
Study Design and Patient Population The investigators conducted a prospective observational study at nine children's hospitals that are members of the Western Pediatric Surgery Research Consortium. IRB approval was obtained from each site with waiver of consent for enrollment. Enrollment took place between 2020-2022. Inclusion criteria were children 1-20 years diagnosed with an ASBO by an attending pediatric surgeon and underwent a trial of nonoperative management (NOM) on hospital admission. The use of an enteral contrast protocol was at the discretion of the attending surgeon. Exclusion criteria included peritonitis, suspicion of incarcerated or internal hernia, active intra-abdominal malignancy, inflammatory bowel disease, <4 weeks since the most recent abdominal operation, pneumatosis, pneumoperitoneum, or known contrast allergy. If the attending surgeon made the decision to take a child directly to the operating room (OR) with no attempt at NOM, these children were excluded. Children under one year of age were excluded as the rate of successful NOM is lower in this age group.
Site details and Contrast Protocols At the start of the study, four of the nine sites had a contrast protocol in place for ASBO diagnosis and management. During the course of the study, contrast protocols were developed and implemented at each of the five additional sites. At study initiation, three sites used contrast routinely, one used it selectively and 5 did not use contrast. At study conclusion, five sites used contrast routinely and four used it selectively.
Contrast agent, volume of contrast, and contrast dilution were not standardized across sites due to the differences in hospital specific formularies; otherwise, the protocol was standardized across sites. Diatrizoate meglumine (osmolality of 1940 mOsm/kg) was used preferentially at eight sites and Ioversol (702 mOms/kg) at one site. Patients received 30-200ml (based on age or weight depending on site) of enteral contrast followed by X-rays at 8-12 hours and 24 hours after contrast administration. Patients were included in the contrast arm if enteral contrast, administered as part of an abdominal CT scan, was followed with subsequent x-rays to assess for progression of contrast to the colon. Failure (complete bowel obstruction) was defined as failure of contrast having not reached the colon by 24 hours after oral administration at which point operative intervention was recommended. The decision to operate was at the discretion of the attending surgeon.
Sample Size Calculation The study was powered to detect a 15% difference in operative rate between the contrast and no contrast groups based on the adult literature. To detect this difference with 80% power, the investigators aimed to enroll 314 patients.
Data Collection and Outcomes Study data were collected and managed using the Research Electronic Data Capture (REDCap) software tool hosted at the University of Colorado. REDCap is a secure, web-based application designed to support data capture for research studies. The surgical inpatient census was monitored daily by study personnel at each site for patients with ASBO. Once identified, data were collected based on a review of the electronic medical record at each site 30 days following hospital discharge. Data collected included patient demographics, medical and surgical history, clinical presentation, laboratory studies, and imaging, management approach including type, volume, dilution of any contrast agent used. Complications specific to the contrast administration including allergic reaction, aspiration of contrast, cardiac arrhythmia, and renal failure were recorded. Details of the hospital course including length of stay, need for operation, indications for operation, and subsequent postoperative course and complications were also included.
Statistical Analysis Descriptive statistics were summarized for continuous variables with medians and interquartile ranges, and for categorical variables with frequencies and percentages. Group differences were tested via t-test or Kruskal-Wallis test for continuous variables and Chi-Squared test or Fisher's Exact test for categorical variables. Comparisons were made between those who received contrast and those who did not. Logistic regression was used to assess the association between contrast and need for operation adjusting for age, body mass index for age z-score (or weight for height z-score for patients under 24 months of age per Centers for Disease Control and Prevention standards), volume of contrast administered, and number of previous laparotomies (< 3 v. ≥3). A subset analysis was performed among patients who received enteral contrast. Comparisons were made based on type of contrast agent used and final osmolality of contrast administered. Additional comparisons were made between only those patients who were successfully managed nonoperatively and then between those patients who required abdominal operation, based on contrast status.
- Being tested
- Enteral contrast challenge
- Keywords
- Pediatric adhesive small bowel obstruction, enteral contrast challenge
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Enteral contrast challengeDiagnostic test
Contrast agent, volume of contrast, and contrast dilution were not standardized across sites due to the differences in hospital specific formularies; otherwise, the protocol was standardized across sites. Diatrizoate meglumine (osmolality of 1940 mOsm/kg) was used preferentially at eight sites and Ioversol (702 mOms/kg) at one site. Patients received 30-200ml (based on age or weight depending on site) of enteral contrast followed by X-rays at 8-12 hours and 24 hours after contrast administration.
| Study group | Role | What they receive |
|---|---|---|
| Contrast Group | Inclusion criteria: children 1-20 years diagnosed with an adhesive small bowel obstruction by an attending pediatric surgeon and underwent a trial of nonoperative management (NOM) on hospital admission and received an enteral contrast challenge. Exclusion criteria included peritonitis, suspicion of incarcerated or internal hernia, active intra-abdominal malignancy, inflammatory bowel disease, <4 weeks since the most recent abdominal operation,45 pneumatosis, pneumoperitoneum, or known contrast allergy. If the attending surgeon made the decision to take a child directly to the operating room (OR) with no attempt at NOM, these children were excluded. Children under one year of age were excluded as the rate of successful NOM is lower in this age group Receives: Diagnostic Test: Enteral contrast challenge | |
| No Contrast group | Inclusion criteria: children 1-20 years diagnosed with an adhesive small bowel obstruction by an attending pediatric surgeon and underwent a trial of nonoperative management (NOM) on hospital admission and who did not receive an enteral contrast challenge. Exclusion criteria included peritonitis, suspicion of incarcerated or internal hernia, active intra-abdominal malignancy, inflammatory bowel disease, <4 weeks since the most recent abdominal operation, pneumatosis, pneumoperitoneum, or known contrast allergy. If the attending surgeon made the decision to take a child directly to the operating room (OR) with no attempt at NOM, these children were excluded. Children under one year of age were excluded as the rate of successful NOM is lower in this age group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of patients who required an operation
operative lysis of adhesions performed due to failure of non operative management
Measured: 1 year
Secondary outcomes (2)
Total hospital length of stay in days
total hospital length of stay among patients successfully managed non operatively
Measured: 1 year
Adverse events resulting from contrast administration
adverse events related to contrast administration
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Oct 2023
- Study start1 Oct 2020
- Primary completion31 Dec 2022
- Study completion31 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Small Bowel ObstructionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 136 participants (actual)
Sponsor and investigators
- Lead sponsor
- Children's Hospital Colorado
- Sponsor type
- University, hospital or other
- Collaborators
- Children's Hospital Los Angeles, University of California, San Francisco, Oregon Health and Science University, Rady Children's Hospital, San Diego, Phoenix Children's Hospital, Primary Children's Hospital, Children's Medical Center Dallas, Seattle Children's Hospital
- Responsible party
- Principal investigator, Shannon Acker, Children's Hospital Colorado
- Investigators
- Shannon N Acker, MD, Principal investigator, Children's Hospital Colorado
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06101719
- Sponsor's protocol ID
- 20-2538
- Acronym
- SBO
- Status last verified
- Aug 2024
- First submitted
- 17 Oct 2023
- Last updated
- 23 Aug 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 23 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Use of a Water Soluble Contrast-Based Protocol to Assist in the Management of Pediatric Adhesive Small Bowel Obstruction
- ClinicalTrials.gov ID
- NCT06101719
- Acronym / sponsor ID
- SBO / 20-2538
- Keywords
- Pediatric adhesive small bowel obstruction, enteral contrast challenge
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 136 participants (actual)
- Lead sponsor
- Children's Hospital ColoradoUniversity, hospital or other
- Collaborators
- Children's Hospital Los Angeles, University of California, San Francisco, Oregon Health and Science University, Rady Children's Hospital, San Diego, Phoenix Children's Hospital, Primary Children's Hospital, Children's Medical Center Dallas, Seattle Children's Hospital
- Study start
- 1 Oct 2020 (actual)
- Primary completion
- 31 Dec 2022 (actual)
- Study completion
- 31 Dec 2023 (actual)
- First posted
- 26 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this prospective observational study is to evaluate the diagnostic and therapeutic utility of an enteral contrast challenge for pediatric patients with adhesive small bowel obstruction (ASBO). The aims are to
- Determine if an enteral contrast challenge is safe in the evaluation of children with ASBO
- Determine if an enteral contrast challenge decreases the need for operation among children with ASBO Children with ASBO who are cared for at one of 9 participating sites who undergo a trial of non operative management will be observed. Comparisons will be made between those who receive and enteral contrast challenge and those who do not. Outcomes to be evaluated include adverse events related to the contrast, rate of operative intervention, and hospital length of stay.
Detailed description
Study Design and Patient Population The investigators conducted a prospective observational study at nine children's hospitals that are members of the Western Pediatric Surgery Research Consortium. IRB approval was obtained from each site with waiver of consent for enrollment. Enrollment took place between 2020-2022. Inclusion criteria were children 1-20 years diagnosed with an ASBO by an attending pediatric surgeon and underwent a trial of nonoperative management (NOM) on hospital admission. The use of an enteral contrast protocol was at the discretion of the attending surgeon. Exclusion criteria included peritonitis, suspicion of incarcerated or internal hernia, active intra-abdominal malignancy, inflammatory bowel disease, <4 weeks since the most recent abdominal operation, pneumatosis, pneumoperitoneum, or known contrast allergy. If the attending surgeon made the decision to take a child directly to the operating room (OR) with no attempt at NOM, these children were excluded. Children under one year of age were excluded as the rate of successful NOM is lower in this age group.
Site details and Contrast Protocols At the start of the study, four of the nine sites had a contrast protocol in place for ASBO diagnosis and management. During the course of the study, contrast protocols were developed and implemented at each of the five additional sites. At study initiation, three sites used contrast routinely, one used it selectively and 5 did not use contrast. At study conclusion, five sites used contrast routinely and four used it selectively.
Contrast agent, volume of contrast, and contrast dilution were not standardized across sites due to the differences in hospital specific formularies; otherwise, the protocol was standardized across sites. Diatrizoate meglumine (osmolality of 1940 mOsm/kg) was used preferentially at eight sites and Ioversol (702 mOms/kg) at one site. Patients received 30-200ml (based on age or weight depending on site) of enteral contrast followed by X-rays at 8-12 hours and 24 hours after contrast administration. Patients were included in the contrast arm if enteral contrast, administered as part of an abdominal CT scan, was followed with subsequent x-rays to assess for progression of contrast to the colon. Failure (complete bowel obstruction) was defined as failure of contrast having not reached the colon by 24 hours after oral administration at which point operative intervention was recommended. The decision to operate was at the discretion of the attending surgeon.
Sample Size Calculation The study was powered to detect a 15% difference in operative rate between the contrast and no contrast groups based on the adult literature. To detect this difference with 80% power, the investigators aimed to enroll 314 patients.
Data Collection and Outcomes Study data were collected and managed using the Research Electronic Data Capture (REDCap) software tool hosted at the University of Colorado. REDCap is a secure, web-based application designed to support data capture for research studies. The surgical inpatient census was monitored daily by study personnel at each site for patients with ASBO. Once identified, data were collected based on a review of the electronic medical record at each site 30 days following hospital discharge. Data collected included patient demographics, medical and surgical history, clinical presentation, laboratory studies, and imaging, management approach including type, volume, dilution of any contrast agent used. Complications specific to the contrast administration including allergic reaction, aspiration of contrast, cardiac arrhythmia, and renal failure were recorded. Details of the hospital course including length of stay, need for operation, indications for operation, and subsequent postoperative course and complications were also included.
Statistical Analysis Descriptive statistics were summarized for continuous variables with medians and interquartile ranges, and for categorical variables with frequencies and percentages. Group differences were tested via t-test or Kruskal-Wallis test for continuous variables and Chi-Squared test or Fisher's Exact test for categorical variables. Comparisons were made between those who received contrast and those who did not. Logistic regression was used to assess the association between contrast and need for operation adjusting for age, body mass index for age z-score (or weight for height z-score for patients under 24 months of age per Centers for Disease Control and Prevention standards), volume of contrast administered, and number of previous laparotomies (< 3 v. ≥3). A subset analysis was performed among patients who received enteral contrast. Comparisons were made based on type of contrast agent used and final osmolality of contrast administered. Additional comparisons were made between only those patients who were successfully managed nonoperatively and then between those patients who required abdominal operation, based on contrast status.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Contrast Group | – | Diagnostic Test: Enteral contrast challengeInclusion criteria: children 1-20 years diagnosed with an adhesive small bowel obstruction by an attending pediatric surgeon and underwent a trial of nonoperative management (NOM) on hospital admission and received an enteral contrast challenge. Exclusion criteria included peritonitis, suspicion of incarcerated or internal hernia, active intra-abdominal malignancy, inflammatory bowel disease, <4 weeks since the most recent abdominal operation,45 pneumatosis, pneumoperitoneum, or known contrast allergy. If the attending surgeon made the decision to take a child directly to the operating room (OR) with no attempt at NOM, these children were excluded. Children under one year of age were excluded as the rate of successful NOM is lower in this age group |
| No Contrast group | – | –Inclusion criteria: children 1-20 years diagnosed with an adhesive small bowel obstruction by an attending pediatric surgeon and underwent a trial of nonoperative management (NOM) on hospital admission and who did not receive an enteral contrast challenge. Exclusion criteria included peritonitis, suspicion of incarcerated or internal hernia, active intra-abdominal malignancy, inflammatory bowel disease, <4 weeks since the most recent abdominal operation, pneumatosis, pneumoperitoneum, or known contrast allergy. If the attending surgeon made the decision to take a child directly to the operating room (OR) with no attempt at NOM, these children were excluded. Children under one year of age were excluded as the rate of successful NOM is lower in this age group |
Who may qualify
- Ages
- 1 year to 20 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Children with adhesive small bowel obstruction admitted to one of 9 participating sites and underwent a trial of non operative management
Key inclusion criteria (3 listed)
- children 1-20 years
- diagnosed with an adhesive small bowel obstruction by an attending pediatric surgeon
- underwent a trial of nonoperative management on hospital admission
Key exclusion criteria (8 listed)
- peritonitis
- suspicion of incarcerated or internal hernia
- active intra-abdominal malignancy
- inflammatory bowel disease
- less than four weeks since most recent abdominal operations
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Enteral contrast challengeContrast agent, volume of contrast, and contrast dilution were not standardized across sites due to the differences in hospital specific formularies; otherwise, the protocol was standardized across sites. Diatrizoate meglumine (osmolality of 1940 mOsm/kg) was used preferentially at eight sites and Ioversol (702 mOms/kg) at one site. Patients received 30-200ml (based on age or weight depending on site) of enteral contrast followed by X-rays at 8-12 hours and 24 hours after contrast administration. | Diagnostic test | Contrast Group |
Primary outcome
Number of patients who required an operation
Time frame: 1 year
operative lysis of adhesions performed due to failure of non operative management
2 secondary outcomes
Total hospital length of stay in days
Time frame: 1 year
Adverse events resulting from contrast administration
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Aug 2024.
- Individual participant dataSharing planned: Undecided
Related trials for Small Bowel Obstruction
Enrolling by invitationObservational study
Intestinal Obstruction Surgery. Acute Abdominal Pathology. №9:05/05/2026
Small Bowel Adhesion, Obstruction Bowel
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Enrolling by invitationObservational study
Management of Non Emergency Adhesive Small Bowel Obstruction:
SBO - Small Bowel Obstruction
RecruitingObservational study
Indiana University Gastrointestinal Motility Diagnosis Registry
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease (GERD)
Recruiting
The Effect of Nasogastric Tube Placement on Complications in Patients With Small Bowel Obstruction - the SBO-TUBE Trial
Small Bowel Obstruction, Intestinal Obstruction and Ileus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Shannon N Acker, MD principal investigator
Children's Hospital Colorado
9 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Small Bowel Obstruction and Contrast Media Adverse Reaction, run by Children's Hospital Colorado at 9 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of patients who required an operation (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Aug 2024.